Literature DB >> 8707418

Monoclonal antibodies against recombinant-MAGE-1 protein identify a cross-reacting 72-kDa antigen which is co-expressed with MAGE-1 protein in melanoma cells.

S Carrel1, M Schreyer, G Spagnoli, J C Cerottini, D Rimoldi.   

Abstract

The MAGE-1 gene codes for tumor-associated peptides recognized by cytolytic T lymphocytes in association with MHC-class-1 molecules such as HLA-A1 and HLA-Cw16. In the course of a study aiming at the immunohistochemical detection of the MAGE-1 gene product in tumor samples, 2 mouse monoclonal antibodies (MAbs) directed against a full-length recombinant MAGE-1 fusion protein were found to react strongly not only with the 46-kDa MAGE-1 protein, but also with a 72-kDa product in immunoblots of lysates obtained from several MAGE-1-mRNA-positive melanoma cell lines. Pre-incubation of the antibodies with the recombinant MAGE-1 fusion protein abolished their reactivity both with MAGE-1 protein and with the 72-kDa product, thus confirming the occurrence of antigenic determinant(s) shared by the 2 proteins. The 72-kDa protein is not an alternative product of MAGE-1, since it was still detected in lysates of a MAGE-1 loss variant derived from a MAGE-1-positive melanoma cell line. Moreover, the 72-kDa protein does not appear to be a product of the other members of the MAGE gene family known to be expressed in tumors (such as MAGE-2, -3, -4 and -12). Interestingly, expression of the 72-kDa protein was found to be correlated with that of MAGE-1 protein. Thus, in 30 tumor cell lines analyzed by immunoblotting and RT-PCR, the 72-kDa protein was never detected in MAGE-1-mRNA-negative cell lines, while it was co-expressed with MAGE-1 protein in 12 out of 15 cell lines expressing MAGE-1. Furthermore, the 72-kDa protein was detected in lysates of human testis, the only normal tissue known to express MAGE-1. Finally, treatment of MAGE-1-mRNA-negative cell lines with 5-Aza-2'-deoxycytidine, a hypomethylating agent known to induce MAGE-1 expression, resulted in the expression of the 72-kDa protein. Taken collectively, these findings suggest that expression of the gene encoding the 72-kDa protein identified in this study through antigenic determinant(s) shared with MAGE-1 protein is regulated in a way similar to that of MAGE-1.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8707418     DOI: 10.1002/(SICI)1097-0215(19960729)67:3<417::AID-IJC17>3.0.CO;2-4

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  4 in total

1.  Vaccination of stage III/IV melanoma patients with long NY-ESO-1 peptide and CpG-B elicits robust CD8+ and CD4+ T-cell responses with multiple specificities including a novel DR7-restricted epitope.

Authors:  P Baumgaertner; C Costa Nunes; A Cachot; H Maby-El Hajjami; L Cagnon; M Braun; L Derré; J-P Rivals; D Rimoldi; S Gnjatic; S Abed Maillard; P Marcos Mondéjar; M P Protti; E Romano; O Michielin; P Romero; D E Speiser; C Jandus
Journal:  Oncoimmunology       Date:  2016-09-09       Impact factor: 8.110

2.  NY-ESO-1 tumour associated antigen is a cytoplasmic protein detectable by specific monoclonal antibodies in cell lines and clinical specimens.

Authors:  E Schultz-Thater; C Noppen; F Gudat; U Dürmüller; P Zajac; T Kocher; M Heberer; G C Spagnoli
Journal:  Br J Cancer       Date:  2000-07       Impact factor: 7.640

3.  Expression of MAGE-1 and -3 genes and gene products in human hepatocellular carcinoma.

Authors:  K Kariyama; T Higashi; Y Kobayashi; K Nouso; H Nakatsukasa; T Yamano; M Ishizaki; T Kaneyoshi; N Toshikuni; T Ohnishi; K Fujiwara; E Nakayama; L Terracciano; G C Spagnoli; T Tsuji
Journal:  Br J Cancer       Date:  1999-11       Impact factor: 7.640

4.  Monoclonal antibody MA454 reveals a heterogeneous expression pattern of MAGE-1 antigen in formalin-fixed paraffin embedded lung tumours.

Authors:  A A Jungbluth; E Stockert; Y T Chen; D Kolb; K Iversen; K Coplan; B Williamson; N Altorki; K J Busam; L J Old
Journal:  Br J Cancer       Date:  2000-08       Impact factor: 7.640

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.